Saber-Moghaddam, 41 patient curcumin early treatment study: 94% lower progression [p=0.001], 38% improved recovery [p=0.04], and 45% shorter hospitalization [p=0.001] https://c19p.org/sabermoghaddam
copied to clipboard
Oral nano-curcumin formulation efficacy in management of mild to moderate hospitalized coronavirus disease-19 patients: An open label nonrandomized clinical trial
et al., Phytotherapy Research, doi:10.1002/ptr.7004
Small prospective nonrandomized trial with 41 patients, 21 treated with curcumin, showing lower disease progression and faster recovery with treatment. IRCT20200408046990N1.
|
risk of progression, 94.3% lower, RR 0.06, p = 0.001, treatment 0 of 21 (0.0%), control 8 of 20 (40.0%), NNT 2.5, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
|
risk of no recovery, 38.4% lower, RR 0.62, p = 0.04, treatment 11 of 21 (52.4%), control 17 of 20 (85.0%), NNT 3.1.
|
|
hospitalization time, 44.8% lower, relative time 0.55, p < 0.001, treatment 21, control 20.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Saber-Moghaddam et al., 1/3/2021, prospective, Iran, Middle East, peer-reviewed, 9 authors.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.